^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dianhydrogalactitol (VAL-083)

    i
    Company:
    Kintara Therap, Valent Tech, Zhongheng Group
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting (NCT02717962)
    Phase 2
    Kintara Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/22/2023
    Initiation :
    01/20/2017
    Primary completion :
    12/30/2023
    Completion :
    03/30/2024
    MGMT
    |
    Avastin (bevacizumab) • temozolomide • dianhydrogalactitol (VAL-083)
    Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression (NCT03050736)
    Phase 2
    Kintara Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/21/2023
    Initiation :
    12/17/2017
    Primary completion :
    11/22/2021
    Completion :
    12/30/2023
    MGMT
    |
    dianhydrogalactitol (VAL-083)
    Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma (NCT01478178)
    Phase 1/2
    DelMar Pharmaceuticals, Inc.
    Completed
    Last update posted :
    01/20/2017
    Initiation :
    10/01/2011
    Primary completion :
    12/01/2015
    Completion :
    10/01/2016
    IDH1 • MGMT
    |
    IDH1 mutation
    |
    dianhydrogalactitol (VAL-083)